ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program,
Section IA-Introduction, Section IV-Administration of Biological Products &
Section VII-Biological Products

Section IA-Introduction

11.0 History of Immunization

- The ‘School Immunization Programs’ and ‘Human Papillomavirus Vaccine’ tables updated to include the replacement of Gardasil® with Gardasil®9 for girls in grade 6.
- ‘Human Papillomavirus Vaccine’ table updated to include the indication of Gardasil®9 for females 9-26 years of age who are HIV positive.
- The ‘Influenza Vaccine’ table updated to include the vaccines being used for the 2016/17 season. Content added regarding:
  - The removal of the preferential use recommendation of live attenuated influenza vaccine (LAIV) for children 2 to 8 years of age.
  - The removal of egg allergy as a contraindication for LAIV.

Please remove page numbers: 21, 29 & 33 dated June 2016
Please add new page numbers: 21, 29 & 33 dated September 2016

Section IV-Administration of Biological Products

11.0 Management of Fever and Pain Following Immunization

- Content added regarding the use of ibuprofen as an alternative to acetaminophen for the management of fever and pain following immunization.
- Reference added to Section IVB-Reducing Immunization Injection Pain for more information regarding strategies to increase child comfort before and during the administration of a biological product.
11.1 Fever Management

- Ibuprofen dosage guidelines added, indicating that this product can be given every 6-8 hours, up to four times in a 24-hour period, and should only be given if the child is well hydrated to reduce the risk of renal adverse events. Also, ibuprofen should not be given to children under 6 months of age without first speaking to a health care professional.
- Content removed regarding the prophylactic use of acetaminophen in children prone to febrile seizures as the current evidence does not support this recommendation.
- Age has been removed from the acetaminophen dosage guidelines table as this is an approximation and dosage for children should be based on weight.

Section VII-Biological Products

**Zoster Vaccine (live attenuated viral vaccine)**

**Zostavax® II**

- Pages re-formatted.
- Biological product name changed from “Varicella Zoster Vaccine” to “Zoster Vaccine”, and trade name updated to Zostavax® II.
- INDICATIONS: revised to indicate that Zostavax® II is not currently publicly funded, however NACI recommends its use for those 60 years of age and older for the prevention of shingles.
- CONTRAINDICATIONS: content related to immunocompromised individuals as a result of disease or therapy has been revised to be consistent with other live vaccines. A footnote has been added regarding the consideration of zoster vaccine for those receiving low dose immunosuppressive therapy, and a reference to the Canadian Immunization Guide (CIG) for more information.
- Clarity has been added to the footnoted content related to varicella susceptible individuals.
- PRECAUTIONS: content related to the use of antiviral medication active against VZV potentially decreasing vaccine effectiveness has been changed from “…taken less than 2 days before or within 14 days after immunization” to “…taken less than 24 hours before or within 14 days after immunization”.
- SPECIAL CONSIDERATIONS: content indicating that zoster vaccine should be stored frozen at an average of -15°C or colder has been removed. This vaccine is to be stored at +2 to 8°C. Content also added recommending an interval of at least one year between an episode of herpes zoster and receipt of the vaccine, based on expert opinion as per the CIG.
Please also remove the Table of Contents for Section VII – Biological Products dated August 2016 and replace with the enclosed updated Table of Contents dated September 2016.

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at christine.halpert@bccdc.ca

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
    Dr. Perry Kendall
    Provincial Health Officer
    Dr. Bonnie Henry
    Deputy Provincial Health Officer
    Craig Thompson
    Director of Immunization
    Healthy Populations and Development Branch
    Warren O’Briain
    Executive Director
    Healthy Populations and Development Branch